Related Experiment Video
Updated: Jul 1, 2026
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 9, 2014
Genistein prevents bone resorption diseases by inhibiting bone resorption and stimulating bone formation
1Department of Oral Pathology, Peking University School of Stomatology, 22 South Zhongguancun Avenue, Haidian District, Beijing 100081, P.R. China. kqlibinbin@yahoo.com.cn
Unlabelled:
Genistein, a soybean-derived isoflavone, has been shown to suppress osteoclastic bone resorption. To clarify the mechanisms underlying this action, we investigated the effects of genistein on the differentiation, cytoskeleton and function in mice osteoclasts in vitro and bone metabolism in ovariectomized rats.
Study Design:
Primary OCs were isolated from 3 week-old mice and induced by 1,25(OH)(2)D(3). Then OCs were exposed to genistein at various concentration of 0 M, 10(-9) M, 10(-8) M, 10(-7) M, 10(-6) M, and 10(-5) M. The number of TRAP+ cells were counted as well as the surface area of bone resorption on bone slice. F-actin change was observed by Confocal. In vivo, forty 12 week-old female SD rats were randomly assigned to four groups: (1) sham operated (Sham); (2) (OVX); (3) ovariectomized and treated with estradiol (OVX-E); (4) ovariectomized and received genistein (OVX-G). After 12 weeks, BMD, body weight, serum level of alkaline phosphatase (ALP), acid phosphatase (ACP), osteocalcin (OC), IL-1beta, TNFalpha, IL-6 and calcitonin (CT) were evaluated. Femur were sectioned. In addition, the serum estradiol, the weight of uteri and histological behavior were also examined to indicate the side effect of genistein to the uteri.
Results:
In vitro, the number of TRAP+ cells decreased depending on the concentration of genistein as well as the area of bone resorption. F-actin became disorder under Confocal. In vivo, after treated with genistein, BMD and the serum level of ALP, ACP, osteocalcin increased significantly, while the serum level of IL-1beta and TNFalpha decreased. Especially, the increase of ALP and osteocalcin of OVX-G was higher than that of OVX-E. Histologically, the pachy-trabecula were observed as well as the more mineral deposition lines. Additionally, the uterus weight index and the serum estradiol in OVX-G rats were lower significantly than those of OVX-E. The epithelia of uteri gland in OVX-G appeared cubic while those of OVX-E became squamous.
Conclusions:
Genistein can prevent bone resorption diseases by the promotion of bone formation and the prevention of bone resorption with slight side effect.
Insights
Genistein, a soy isoflavone, effectively prevents bone resorption and promotes bone formation. This study shows genistein
Area of Science:
- Biochemistry and Molecular Biology
- Bone Biology and Metabolism
- Pharmacology
Background:
- Osteoclastic bone resorption is a key process in bone metabolism.
- Genistein, a soybean isoflavone, is known to inhibit osteoclast activity.
- Understanding genistein's precise mechanisms is crucial for developing bone-protective therapies.
Purpose of the Study:
- To investigate the effects of genistein on osteoclast differentiation, cytoskeleton, and function in vitro.
- To evaluate the impact of genistein on bone metabolism in an in vivo model of bone loss.
Main Methods:
- In vitro: Primary mouse osteoclasts were treated with varying concentrations of genistein. Osteoclast activity markers (TRAP+ cells, bone resorption area, F-actin) were assessed.
- In vivo: Ovariectomized (OVX) rats were treated with genistein or estradiol. Bone mineral density (BMD), biochemical markers, and uterine histology were analyzed.
Main Results:
- Genistein suppressed osteoclast differentiation and bone resorption in vitro.
- In vivo, genistein treatment increased BMD and bone formation markers (ALP, osteocalcin) while reducing inflammatory cytokines (IL-1beta, TNFalpha).
- Genistein showed comparable or superior bone benefits to estradiol with fewer side effects on uterine tissue.
Conclusions:
- Genistein demonstrates potential as a therapeutic agent for bone resorption diseases.
- It promotes bone formation and inhibits bone resorption.
- Genistein exhibits a favorable safety profile with minimal side effects.
Related Concept Videos
01:40Bone Remodeling
01:31Osteoclasts in Bone Remodeling
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:31Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...